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Here we investigate the feasibility of tumor metabolism monitoring in T1c to T3 breast cancer during neoadjuvant
chemotherapy by means of phosphorus (31P) magnetic resonance spectroscopy at 7 tesla (T). Five breast cancer
patients were examined using a 31P MRSI sequence, prior to-, halfway-, and after neoadjuvant chemotherapy. The 31P
MRSI data were analyzed on group and individual level and compared to a spectrum of a group of healthy volunteers.
Ratios of phosphomonoesters (PME) to phosphodiesters (PDE) and phosphomonoesters to inorganic phosphate (Pi)
were determined. Histopathologic assessment showed four partial responders and one complete responder to
chemotherapy. The 31P spectrum of the patient group was distinctly different from the 31P spectrum of healthy
volunteers and transformed its shape during the course of chemotherapy towards the shape of the spectrum of the
healthy volunteers. Prior to chemotherapy the PME to PDE signal ratio and the PME to Pi signal ratio were high, and
during the course of the chemotherapy these ratios normalized to the value of the healthy volunteers. Metabolite T2
values in tumor tissue tended to be lower than those for healthy glandular tissue. Assessment of individual patients
showed that four out of five had a significant drop of the PME to Pi ratio by a factor of 2 or more. On average, the pH
of the tumor, calculated from chemical shift variation of Pi, was 0.19 units lower before chemotherapy. We have
demonstrated that the sensitivity of 31P MRSI in breast cancer at 7 T is sufficient to detect alterations in membrane
metabolism during neoadjuvant chemotherapy, which may be used for early assessment of treatment efficacy.
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Breast cancer is by far the most prevalent type of cancer in
women worldwide (Jemal et al. 2011). Surgical breast can-
cer treatment is sometimes preceded by a neoadjuvant
therapy such as chemotherapy, endocrine therapy, and or
targeted therapy. Neoadjuvant therapy is applied in patients
with inoperable inflammatory or locally advanced breast
cancer and nowadays also in patients with operable breast
cancer to reduce tumor volume to enable breast conserving
surgery (Liu et al. 2010). Although reduction of the tumor
volume is achieved in the majority of patients, a pathologic
complete response is only seen in less than 20% of patients
according to a recent meta-analyses which included almost* Correspondence: w.j.m.vanderkemp@umcutrecht.nl
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reproduction in any medium, provided the orig3800 breast cancer patients receiving neoadjuvant therapy
(Kong et al. 2011). Because of this low pathologic complete
response that is often used to predict survival rate, there is
a need for early assessment of neoadjuvant chemotherapy
efficacy, which would enable switching to a possibly more
successful agent early in therapy. In contrast to imaging,
that monitors the tumor’s morphology alterations during
neoadjuvant therapy, the monitoring of tumor metabolism
may offer a faster and better window to assess therapy effi-
cacy. Phosphorus magnetic resonance spectroscopy (31P
MRS) is probably the most suitable tool to achieve this,
because the metabolites of interest are phosphorus com-
pounds such as the phosphomonoesters (PME) phospho-
choline (PC) and phosphoethanolamine (PE) and the
phosphodiesters (PDE) glycerophosphocholine (GPC) and
glycerophosphoethanolamine (GPE) that are involved inThis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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1999; Glunde et al. 2004). In addition to these metabolites,
signals of mobile phospholipids glycerophosphatidylcholine
(GPtC) and glycerophosphatidylethanolamine (GPtE), but
also metabolites involved in energy metabolism such as in-
organic phosphate (Pi) and adenosinetriphosphate (ATP)
can be measured with 31P MRS.
Although hampered by a relatively low intrinsic sensitiv-
ity, 31P MRS offers substantial benefits above proton (1H)
MRS in monitoring tumor metabolism. In vivo measure-
ment of these individual 31P metabolites is feasible with 31P
MRS, while in vivo proton MRS can only assess a ‘total-
choline’ signal that comprises the sum of monoesters and
diesters. In contrast to 1H MRS, that necessitates water
suppression that may bias the total choline signal, phos-
phorous MRS doesn’t require water suppression. Moreover
the chemical shift of Pi, as measured in 31P MRS may serve
as a proxy for intracellular pH and tumor hypoxia.
The first clinical application of 31P MRS in monitoring
neoadjuvant chemotherapy in breast cancer patients was
reported in 1989 by Ng et al. (1989), after which a number
of reports followed (Glaholm et al. 1989; Redmond et al.
1992; Twelves et al. 1994; Leach et al. 1998). All of these
studies were performed at low magnetic field, having
insufficient spectral resolution to resolve the individual
phosphomonoester (PE, PC) signals or individual phospho-
diester (GPE, GPC and mobile GPtE and GPtC) signals.
Moreover, the sensitivity at these lower field strengths could
only detect MR spectra from very large tumors, often
involving almost the entire breast. Nonetheless, these previ-
ous studies report increased PME signal prior to therapy
and decreasing PME during therapy for responders and
partial responders. After the publication of Leach et al.
(1998), it took 13 years to improve 31P MRS in breast can-
cer to facilitate clinical studies in more relevant tumor sizes.
First of all, the field strength was increased from 1.5 T to
7 T, and efficient quadrature RF coils were designed dedi-
cated to the human breast (Klomp et al. 2011). All together
this improved sensitivity by an order of magnitude; a factor
of 2 from 1.5 T to 3 T and more than a factor of 5 from
3 T to 7 T using the dedicated breast coil (Korteweg et al.
2011). Moreover, improved MRS sequences were developed
that include spatial localization techniques and means toFigure 1 Adiabatic multi-echo spectroscopic imaging (AMESING) sequmaximize sensitivity even further by using adiabatic multi-
echo spectroscopic imaging (AMESING) (van der Kemp
et al. 2013).
In this work we investigate whether state of the art 31P
MRSI is sufficiently sensitive to pick up PME alterations
in the primary tumor in patients with breast cancer during
the course of neoadjuvant chemotherapy.
Methods
Patients
From the period February 2012 to August 2013, six patients
diagnosed with breast cancer (one T1c, four T2 and one T3
stage cancer) who were scheduled for neoadjuvant chemo-
therapy at our institute were asked to participate in this
study. The study protocol was approved by the Medical
Ethics Committee of the Utrecht University Medical Center
and all patients gave written informed consent. All patients
received 6 doses of chemotherapy; either 6x FEC (fluoro-
uracil + epirubicine + cyclophosphamide) or 3× FEC
followed by 3× docetaxel. Patients underwent a 31P MRSI
scan prior to-, half way- and after chemotherapy. Patients
underwent surgery within a week after the last scan and
chemotherapy efficacy was assessed by histopathology. This
study is registered at trialregister.nl: NTR4652.
MRI and MRSI
Patients were scanned in prone position on a 7 T MR scan-
ner (Philips Healthcare, Cleveland, OH, USA) using a unilat-
eral two channel double tuned RF breast coil (MR Coils BV,
Drunen, the Netherlands). The scan session contained a fat
suppressed T1 weighted 3D MRI (TE =2 ms, TR =4 ms,
binominal 10 degree flip angle, FOV, resolution 1 mm3).
B0-shimming was obtained over the breast using the stand-
ard Philips pencil beam shimming (Gruetter 1993). 31P
MRSI was obtained using the AMESING sequence
(Figure 1), in which 1 FID and 5 full echoes were acquired
with ΔTE =45 ms; TR =6 s; FOV 160×160×160 mm
3; 8×8×8
voxels; (2 cm)3 nominal resolution; BW =8200 Hz; sampling
matrix size =256; total scan time 25:36 min.
Data analysis
Acquired data were zerofilled in the time domain and
spatially Hamming filtered. The voxel containing theence (van der Kemp et al. 2013).
van der Kemp et al. SpringerPlus 2014, 3:634 Page 3 of 7
http://www.springerplus.com/content/3/1/634breast tumor was selected using 3DiCSI (Zhao et al.
2007) for visualisation. Spectra (1 FID and 5 full echoes)
from tumor voxels of the patients, prior (P), halfway
(HW), and after (A) neoadjuvant chemotherapy were
frequency aligned for PE and weighted for the PE inten-
sity of the FID to maximise SNR of the patient group
spectra. The weighted sum FID spectra and the five
weighted sum spectra of the full echoes, at the three
points in time, were spectrally fitted in JMRUI (Naressi
et al. 2001) using the AMARES (Vanhamme et al. 1997)
algorithm. Average chemical shifts of the metabolites
were calculated prior, halfway, and after neoadjuvant
chemotherapy from FID and echo spectra. Prior to
quantification the spectra were apodized with 40 Hz.
During spectral fitting overall phases were fixed to zero,
the linewidths of PE, PC and Pi were fixed to 55 Hz and
the linewidth of GPtE + GPC in the FID was fixed to
65 Hz and in the echoes to 55 Hz (where predominantly
GPC is left), the linewidth of GPtC was fixed to 65 Hz.
The chemical shift of PE was kept in the range of 6.7 to
6.9 ppm, of GPtE + GPC in the range 2.7 to 2.9 ppm.
Frequency differences between PE and PC, GPtE + GPC
and GPtC, GPE and GPC were kept at 68 Hz. Metabolic
signal ratios for PE/(GPtE + GPC), PC/GPtC, PME/PDE,
and PME/Pi were calculated from spectral fitting.
Weighted sum spectra of the patient group for the 5 full
echoes were spectrally fitted as well and both FID andFigure 2 Patient group FID spectra during neoadjuvant chemotherap
volunteers. Data from healthy volunteers were obtained recently in our gr
measured four times with four times larger voxel sizes leading to a high SN
metabolite signal intensities during therapy.echo data were used to calculate metabolite T2 values.
95% Confidence intervals for the metabolite T2 values
were calculated by means of Monte Carlo simulations.
Metabolic signal ratios for the individual patients dur-
ing the course of neoadjuvant chemotherapy were calcu-
lated based on T2-weighting of the FID and the five
symmetric echoes that were acquired for the tumor vox-
els. Metabolic T2-weighting was based on an assumed
proportionality between accurately known average T2-
values of 31P metabolites in healthy glandular tissue
(Stehouwer et al. 2014) and those values in tumor tissue.
To this end the 31P spectrum of a voxel containing the
tumor was SNR optimized for all signals by fitting the
same proportionality constant for all metabolites while
applying the T2-weighting.
Results and discussion
Within a time frame of 17 months, six patients partici-
pated in this study. One patient dropped out after the first
scan session due to claustrophobia. Cancer type and re-
ceptor status of the breast cancers were assessed from
core needle biopsies. Two patients of the group who suc-
cessfully concluded this study were diagnosed with inva-
sive ductolobular carcinoma, two with invasive ductal
carcinoma, and one with medullary carcinoma. Three pa-
tients had receptor status ER +, PR +, Her2neu – and two
were triple negative. Histopathologic assessment showedy as compared to a FID spectrum of a group of healthy
oup by Stehouwer et al. (2014) and are based on 7 volunteers
R group spectrum. The straight lines emphasize the change in
Figure 3 PME and PDE metabolic signal ratios obtained by spectral fitting of FID group spectra of patients during neoadjuvant
chemotherapy as compared to a group spectrum of 7 healthy volunteers. P: Prior-; HW: Halfway-; A: After neoadjuvant chemotherapy;
H: healthy.
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consisted of one full responder and four partial re-
sponders. After chemotherapy the full responder still had
a fibroadenoma surrounding the tumor location.
The FID spectra during neoadjuvant chemotherapy for
the patient group are shown in Figure 2. For comparison, a
FID spectrum of a healthy volunteer group consisting of
seven healthy volunteers measured four times and with a
four times larger nominal voxel size is shown as well
(Stehouwer et al. 2014). There are a number of distinct fea-
tures that distinguish the presented breast cancer spectra
from the healthy volunteer group spectrum. These distinct
features are most prominent when comparing the patient
spectrum acquired prior to chemotherapy with the healthyFigure 4 Average PME over PDE signal ratios during the course of ne
grey, with physiological variation) and calculated from averaged pativolunteer group spectrum. Prior to chemotherapy the pa-
tient group spectrum shows higher: PE than Pi, PE than
GPtE +GPC, and PE than GPtC. The signals of γ-ATP and
α-ATP are higher than the PDE signals. In the healthy vol-
unteer group spectrum theses patterns are reversed. During
chemotherapy (half way and after chemotherapy) the pa-
tient group spectra are showing more resemblance to the
healthy volunteer group spectrum.
In Figure 3 the PME to PDE signal ratios (PME/PDE,
PE/(GPtE + GPC), PC/GPtC) and the PME to Pi meta-
bolic signal ratios, as obtained from spectral fitting the
FID group spectra, are shown during the course of
chemotherapy, also in comparison to the healthy volun-
teer data by Stehouwer et al. (2014). Except for PC/GPtC,oadjuvant chemotherapy calculated for individual patients (light
ent group spectra (dark grey, without physiological variation).
Figure 5 Individual patient metabolic signal ratios of PME over Pi, during the course of chemotherapy, relative to healthy glandular
tissue. P: Prior-; HW: Half Way-; A: After neoadjuvant chemotherapy. For a value of 1.0 the PME over Pi signal ratio of patient equals that ratio in
healthy glandular tissue. Note that all patients showed a higher PME over Pi ratio than 1.0 prior to therapy.
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the patient group PE/(GPtE +GPC), PME/PDE and PME/
Pi show the same decreasing pattern during the course of
chemotherapy and all normalize to values observed in
healthy volunteers.
The metabolic signal ratios of the averaged group spectra
shown in Figure 3 are based on average group signals (no
physiological variability) and system noise (i.e. Cramer Rao
lower bounds (De Graaf 2007) is represented by the error
bars. In Figure 4 the PME over PDE ratios are shown as an
average based on the individual patient data –including
physiological variation as an error bar– and averaged group
data with system noise as an error bar. The largest physio-
logical variation between patients is seen in the PME over
PDE ratios prior to chemotherapy as may be expected from
this heterogeneous patient group with three ER+/PgR + and
two triple negative patients. In preclinical work and animal
studies it has been shown that triple negative breast cancersFigure 6 Calculated metabolite T2 values and 95% confidence interva
cancer patient group during neoadjuvant chemotherapy.have a low PME to PDE ratio in contrast to ER+/PR + tu-
mors which have a high PME to PDE ratio (Moestue et al.
2010; Esmaeili et al. 2014).
Patient signal ratios of PME over Pi relative to healthy
glandular tissue are shown during the course of chemother-
apy, in Figure 5. Here, a ratio of 1.0 implies that patients
PME over Pi signal ratio equals that of healthy glandular
tissue.
Prior to neoadjuvant chemotherapy, four out of five pa-
tients show significantly higher PME over Pi signal ratios
than encountered in healthy glandular tissue. After chemo-
therapy, one out of five patients shows a significantly lower
PME over Pi signal ratio than encountered in healthy glan-
dular tissue, while the other four patients have PME over Pi
signal ratios similar to those in healthy glandular tissue.
The PME over Pi ratio is a tissue viability marker that can
be used in for instance assessing kidney quality for trans-
plantation (Bretan et al. 1989), where a high ratio designatesls for several phosphorus containing metabolites in a breast
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an early marker for tumor cell apoptosis (Sakurai et al.
1998). However, pre-thermoradiotherapy PME to Pi ratios
in sarcomas inversely correlate to pathologic complete re-
sponse (Dewhirst et al. 2005).
Calculated metabolite T2 values with 95% confidence
intervals are shown in Figure 6 during chemotherapy
and for healthy volunteers.
Metabolite T2 values fitted from low-SNR data are prone
to be overestimated, as is evident from the asymmetric con-
fidence intervals in Figure 6. Significantly lower T2 values
than in healthy volunteers are seen for PE(HW), PC(P), Pi
(P, HW, A) and GPtE +GPC(HW). Overall there is a trend
for lower 31P metabolite T2 values in these breast cancer
patients, as compared to the metabolite T2 values in healthy
fibroglandular tissue. This matches the lower T2 values of
water in prostate tumors as reported by Roebuck et al.
(Roebuck et al. 2009). The significant higher T2 for the
(GPtE +GPC) signal prior to chemotherapy is possibly
caused by increased GPC prior to chemotherapy in this pa-
tient group, that includes two triple negative breast cancer
patient cases. It is likely that GPtE has a T2-value similar
to GPtC, i.e. in the order of 20 ms, while GPC is likely to
have a T2 value that is in the range of the phosphomonoe-
sters or even higher. In calf muscle for instance it exceeds
300 ms at 7 T (Bogner et al. 2009). This implies that on
average the phosphodiester GPC signal (and concentra-
tion) is higher prior to chemotherapy and decreases dur-
ing therapy in this patient group, which is contrary to the
general, probably too simplistic, paradigm of increasing
glycerophosphocholine and -ethanolamine during suc-
cessful chemotherapy. This is corroborated by a report on
the difference in choline metabolic profile of basal like
and luminal like breast cancer xenografts by Moestue
et al. (2010), where it was found that triple negative/basal
like breast carcinomas had high GPC/PC ratios.
For the patient group as a whole the average chemical
shift of Pi shows an increase of +0.14 ± 0.05 ppm over the
course of the chemotherapy, which corresponds to a shift
in pH of 0.19 units, implying a more acidic environment
before the start of the chemotherapy, possibly indicative of
tumor hypoxia or lactate formation.
In conclusion, using state of the art 31P MRSI provides
sufficient sensitivity to detect statistically significant
phospholipid alterations in primary breast tumors during
neoadjuvant chemotherapy, despite the limited and het-
erogeneous sample size. Moreover, the 31P spectrum of
the patient group obtained prior to treatment is dis-
tinctly different from the 31P spectrum of glandular tis-
sue in the healthy volunteer group and transforms its
shape during the course of the chemotherapy towards
the shape of the spectrum of the healthy volunteer
group. In line with our prospective hypothesis, the ele-
vated phosphomonoesters in breast tumors decreaseduring the course of the chemotherapy. In addition, due
to the high spectral resolution at 7 T, a subtle tumor pH
increase of 0.19 units is observed during the treatment,
possibly indicating tumor hypoxia or lactate formation.
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